Loading...
Loading...
Browse all stories on DeepNewz
VisitAutolus Therapeutics Gains FDA Approval for AUCATZYL® (obe-cel) CAR-T Therapy in Leukemia
Nov 11, 2024, 12:14 PM
Autolus Therapeutics has received FDA approval for its CAR-T therapy, AUCATZYL® (obecabtagene autoleucel – obe-cel), for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This marks the first product approval for the UK-based biotech company. Autolus stock rose 9.9% pre-market following the announcement.
View original story
Markets
No • 50%
Yes • 50%
Autolus Therapeutics' quarterly financial reports
No • 50%
Yes • 50%
Official announcements from Autolus Therapeutics
Yes • 50%
No • 50%
Stock market data from financial news platforms
Best New Drug • 25%
Other • 25%
No major award • 25%
Innovation in Oncology • 25%
Industry award announcements
Bristol Myers Squibb • 25%
Novartis • 25%
Gilead Sciences • 25%
Other • 25%
FDA approval announcements
Acquisition by another company • 33%
No partnership or acquisition • 34%
Partnership with a pharmaceutical company • 33%
Official announcements from Autolus Therapeutics